MoonLake CFO sells 2,426 shares at $19.56

MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt sold 2,426 Class A ordinary shares in an open-market transaction.

Rhea-AI Filing Summary

MoonLake Immunotherapeutics Chief Financial Officer Matthias Bodenstedt sold 2,426 Class A ordinary shares in an open-market transaction. The shares were sold on April 14, 2026 at a weighted average price of $19.56 per share, in multiple trades between $19.50 and $19.625.

After this transaction, he directly holds 1,186,084 Class A ordinary shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating it was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 2,426 shares

Net Sell 1 txn

Insider Bodenstedt Matthias

Role Chief Financial Officer

Sold 2,426 shs ($47K)

Type	Security	Shares	Price	Value
Sale	Class A ordinary shares, par value $0.0001 per share	2,426	$19.56	$47K

Holdings After Transaction: Class A ordinary shares, par value $0.0001 per share — 1,186,084 shares (Direct)

Footnotes (2)

1. F1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
2. F2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.625. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Key Figures

Shares sold: 2,426 shares Weighted average sale price: $19.56 per share Post-transaction holdings: 1,186,084 shares +2 more

5 metrics

Shares sold 2,426 shares Open-market sale on April 14, 2026

Weighted average sale price $19.56 per share Class A ordinary shares sold April 14, 2026

Post-transaction holdings 1,186,084 shares Shares directly held after April 14, 2026 sale

Price range of sales $19.50 to $19.625 Multiple transactions comprising the 2,426-share sale

Rule 10b5-1 plan adoption date December 10, 2025 Trading plan governing the April 14, 2026 sale

Key Terms

Rule 10b5-1 trading plan, weighted average sale price, Class A ordinary shares, open-market sale

4 terms

Rule 10b5-1 trading plan regulatory

"This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average sale price financial

"The price reported represents the weighted average sale price per share."

Class A ordinary shares financial

"Class A ordinary shares, par value $0.0001 per share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MoonLake Immunotherapeutics (MLTX) report for its CFO?

MoonLake Immunotherapeutics reported that CFO Matthias Bodenstedt sold 2,426 Class A ordinary shares. The transaction was an open-market sale executed on April 14, 2026 at a weighted average price of $19.56 per share, under a pre-arranged Rule 10b5-1 trading plan.

How many MoonLake (MLTX) shares does the CFO hold after the reported sale?

After the sale, CFO Matthias Bodenstedt holds 1,186,084 Class A ordinary shares directly. This filing shows only a small portion of his overall stake was sold, with the majority of his share ownership remaining in place following the April 14, 2026 transaction.

At what price did the MoonLake (MLTX) CFO sell his shares?

The reported weighted average sale price was $19.56 per share. According to the filing, the 2,426 shares were sold in multiple transactions at prices ranging from $19.50 to $19.625, with the weighted average used as the disclosed transaction price.

Was the MoonLake (MLTX) CFO’s share sale part of a Rule 10b5-1 plan?

Yes. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. Such plans schedule trades in advance, which can indicate the transaction timing was pre-arranged rather than based on short-term market developments or new, non-public information.

What type of security did the MoonLake (MLTX) Form 4 transaction involve?

The transaction involved Class A ordinary shares with a par value of $0.0001 per share. These are non-derivative equity securities of MoonLake Immunotherapeutics, and the Form 4 records an open-market sale of 2,426 of these shares by the company’s Chief Financial Officer.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/16/2026 - 04:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bodenstedt Matthias

(Last) (First) (Middle)

C/O MOONLAKE IMMUNOTHERAPEUTICS

DORFSTRASSE 29

(Street)

ZUG 6300

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
MoonLake Immunotherapeutics [ MLTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A ordinary shares, par value $0.0001 per share	04/14/2026		S(1)		2,426	D	$19.56(2)	1,186,084	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $19.500 to $19.625. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

	/s/ Matthias Bodenstedt	04/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)